Combined Radiotherapy and Radiofrequency Ablation for Hepatocellular Carcinoma
NCT04202523 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2019-12-17
Summary
Liver cancer is a clinically high-grade malignant tumor, and the current incidence rate is increasing year by year. It has become the third most malignant tumor after gastric cancer and lung cancer, and has a high mortality rate. The patient's five-year survival rate is less than 8.5%, which the second leading cause of cancer death is a serious threat to the health of patients. Surgical resection is the preferred treatment plan for liver cancer. With the development of medical technology, the clinical efficacy of liver cancer has been significantly improved, but postoperative recurrence has not been effectively controlled. According to statistics, the recurrence rate of liver cancer after 5 years is as high as 77.0%. Even for small liver cancer resection, the recurrence rate is 40.0%\~50.0% within 5 years after operation. At the same time, for recurrent liver cancer, surgical resection is still the preferred treatment plan, but affected by the location, size, distal metastasis and multi-center pathogenesis of liver cancer, only 10.4%\~31.0% can be surgically removed. In recent years, RFA has been widely used in liver cancer and recurrent liver cancer due to its unique advantages such as minimally invasive, simple operation, wide indication, reproducible, low cost, and accepted by patients, and has achieved satisfactory results. However, study found that because of the special location of recurrent liver cancer, its multi-center origin, and the characteristics of intrahepatic micrometastasis, it is often accompanied by microvascular tumor thrombus (MVI), which greatly increases the risk of liver cancer recurrence. Moreover, since the treatment of RFA can only be effective for the local detection of recurrent foci, and the effect of detecting small lesions is poor, there is a higher risk of recurrence. The use of radiation therapy is getting more and more attention, and it is changing from the past palliative treatment to current curable treatment. From an oncologic point of view, a narrow margin \<1 cm and microvascular invasion is not safe and is often associated with higher rates of recurrence and shorter patient survival. On the other hand, it is also believed that most intrahepatic recurrences arise from multicentric carcinogenesis and are distant from the resection margin.
Whether combined radiotherapy and RFA treatment of liver cancer and recurrent liver cancer can further improve the clinical efficacy, there are few reports. Therefore, the short-term and long-term effects of radiotherapy combined with RFA in the treatment of liver cancer and recurrent liver cancer are studied to provide guidance for clinical treatment.
Conditions
Interventions
- RADIATION
-
Radiofrequency ablation
Liver cancer radiofrequency ablation is a clinical treatment method that uses electrode needles to penetrate the skin and liver into the tumor and completely destroy the tumor through the principle of heat production to achieve the purpose of treating tumors.
- DEVICE
-
IMRT & SBRT
Tumor radiation therapy is a local treatment method using radiation to treat tumors. Radiation includes alpha, beta, and gamma rays produced by radioactive isotopes and x-rays, electron beams, proton beams, and other particle beams produced by various types of x-ray therapy machines or accelerators. Current mainstream radiotherapy technologies include stereotactic radiation therapy (SRT). Stereotactic radiation therapy (SRT) includes three-dimensional conformal radiation therapy (3DCRT) and three-dimensional conformal intensity modulated radiation therapy (IMRT).
Sponsors & Collaborators
-
Guangxi Medical University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-12-01
- Primary Completion
- 2020-12-01
- Completion
- 2020-12-31
Countries
- China
Study Locations
More Related Trials
-
Intensity-modulated Radiotherapy (IMRT) With Simultaneous Integrated Boost (SIB) for Inoperable Non-small-cell Lung Cancer
NCT02841228 ·Status: UNKNOWN ·Phase: PHASE2
-
Fusion Guided Thermal Ablation Combined With External Beam Radiation for Hepatic Neoplasms
NCT01862718 ·Status: TERMINATED ·Phase: PHASE1
-
The Effect of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma
NCT03143140 ·Status: UNKNOWN ·Phase: NA
-
Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma
NCT03614546 ·Status: UNKNOWN ·Phase: NA
-
Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.
NCT06205472 ·Status: RECRUITING ·Phase: PHASE2
-
Hepatocellular Carcinoma Treated With Iodine-125 Implantation
NCT01717729 ·Status: COMPLETED ·Phase: PHASE3
-
Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma
NCT03609268 ·Status: UNKNOWN ·Phase: NA
-
Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma
NCT06168292 ·Status: RECRUITING ·Phase: NA
-
SBRT for Liver Cancer Before Liver Transplantation
NCT04186234 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases
NCT06567353 ·Status: RECRUITING ·Phase: NA
-
SBRT With DIBH for HCC After TACE and Lipiodol Marking
NCT05021250 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Comparison of Efficacy in SBRT of Large HCC With or Without TACE
NCT04512846 ·Status: RECRUITING
-
Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors
NCT04242342 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Radiotherapy or Observation of Liver Metastases in Small Cell Lung Cancer
NCT05150145 ·Status: RECRUITING ·Phase: NA
-
Evaluate the Efficacy of Radiofrequency Ablation/Vertebroplasty with or Without SBRT for Treating Painful Spinal Vertebral Metastases
NCT06756087 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study
NCT05602974 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
HA-WBRT-SIB for Brain Metastasis of Lung Cancer
NCT06289023 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma
NCT01247298 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
NCT00777894 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma
NCT02113423 ·Status: COMPLETED ·Phase: NA
-
Magnetic Resonance Imaging-guided Thermal Radiofrequencey Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases
NCT00006255 ·Status: COMPLETED ·Phase: PHASE2
-
Magnetic Resonance-guided Adaptive Stereotactic Body Radiotherapy for Hepatic Metastases
NCT05027711 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase II Study of Radiotherapy for Locally Advanced Hepatocellular Carcinoma (HCC)
NCT00154817 ·Status: COMPLETED ·Phase: PHASE2
-
Displacement Distance and Stabilization Time for Liver Fiducial Marker
NCT05816837 ·Status: UNKNOWN
-
Study of Outcomes of Radiofrequency Ablation of Lung Tumors
NCT00280189 ·Status: SUSPENDED